Общество с ограниченной ответственностью "Консорциум-ПИК" (RU)
发明人:
Глезер Мария Генриховна (RU),Асташкин Евгений Иванович (RU),Киселева Алена Евгеньевна (RU)
申请号：
RU2014147357
公开号：
RU2014147357A
申请日:
2014.11.25
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. Use of L-carnitine solution for intravenous and intramuscular injection as an agent for reducing the risk of increasing QT dispersion in patsienta.2. Use according to claim. 1, characterized in that the patient is a patient suffering from acute coronary sindromom.3. Use according to claim 2, characterized in that the patient is a patient suffering from at least one disease selected from the group:. Unstable angina, acute myocardial infarction.4. A method of reducing the risk of increasing QT dispersion in a patient, comprising the steps that 0.4 g of L-carnitine in solution for intravenous or intramuscular administration to a patient intravenously administered 2 times a day for the first 3 days of beginning treatment, after which the dose is reduced by half and continuing to introduce said solution to a patient intravenously for 12 days or until the favorable effekta.5. A method according to claim. 4, wherein the patient is a patient suffering from acute coronary sindromom.6. A method according to claim 5, wherein the patient is a patient suffering from at least one disease selected from the group:. Unstable angina, acute myocardial miokarda.7. A pharmaceutical agent for reducing increased risk of QT dispersion in a patient, comprising L-carnitine, which is a solution for intravenous and intramuscular vvedeniya.8. The pharmaceutical agent of claim. 7, characterized in that the patient is a patient suffering from acute coronary sindromom.9. The pharmaceutical agent of claim 8, wherein the patient is a patient suffering from at least one disease selected from the group:. Unstable angina, acute myocardial miokarda.10. pharmaceutical environments1. Применение раствора L-карнитина для внутривенного и внутримышечного введения в качестве средства для снижения риска увеличения дисперсии QT у пациента.2. Применение по п. 1, отличающееся тем, что пациентом является пациент, страдающий острым коронарным синдромом.3. Применение по п. 2, отличающееся тем, что пациентом являет
